Johnson & Johnson $JNJ Shares Acquired by First Financial Bankshares Inc

First Financial Bankshares Inc increased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 641,717 shares of the company’s stock after purchasing an additional 2,834 shares during the quarter. Johnson & Johnson accounts for about 3.0% of First Financial Bankshares Inc’s investment portfolio, making the stock its 8th largest holding. First Financial Bankshares Inc’s holdings in Johnson & Johnson were worth $169,888,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. CKW Financial Group raised its holdings in shares of Johnson & Johnson by 0.9% during the third quarter. CKW Financial Group now owns 4,269 shares of the company’s stock worth $1,104,000 after purchasing an additional 37 shares during the period. Silver Coast Investments LLC lifted its position in shares of Johnson & Johnson by 3.8% in the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock worth $271,000 after buying an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV boosted its holdings in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock valued at $1,630,000 after buying an additional 39 shares during the period. Triumph Capital Management boosted its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock valued at $643,000 after buying an additional 39 shares during the period. Finally, Kwmg LLC boosted its holdings in shares of Johnson & Johnson by 1.7% in the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company’s stock valued at $631,000 after buying an additional 39 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Citigroup raised their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Johnson Rice downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. HSBC upped their target price on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, Erste Group Bank cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $275.92.

View Our Latest Stock Analysis on Johnson & Johnson

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 13,072 shares of the company’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,832,923.66. The trade was a 43.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

JNJ stock opened at $282.62 on Tuesday. Johnson & Johnson has a 1 year low of $195.90 and a 1 year high of $290.25. The stock has a market capitalization of $680.36 billion, a price-to-earnings ratio of 42.82, a PEG ratio of 2.80 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The stock’s fifty day moving average is $267.12 and its two-hundred day moving average is $250.12.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, research analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is 81.21%.

Latest Johnson & Johnson News

These are some of the JNJ news items that stood out recently:

  • Positive Sentiment: J&J will pay $2.2 billion upfront for Ollin, with up to about $1.1 billion in additional regulatory and commercial milestone payments. The acquisition adds OLN324, a late-stage antibody being developed for wet age-related macular degeneration and diabetic macular edema, and could complement J&J’s existing eye-care business. J&J bets $2.2B on Ollin’s vision loss drug
  • Positive Sentiment: Blackstone Life Sciences will provide $750 million to fund OLN324’s Phase 3 program, helping support development of the drug while sharing its funding burden. Blackstone Life Sciences Announces $750 Million R&D Funding Agreement
  • Neutral Sentiment: OLN324 is still investigational, so its commercial prospects depend on successful trials, regulatory approval and uptake. The retinal-disease market is crowded and competitive, which could limit eventual returns on the acquisition. J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.